Bayer Pharma Aktiengesellschaft;Bayer HealthCare Pharmaceuticals Inc.
发明人:
LIU NINGSHU,PENA CAROL,JEFFERS MICHAEL,GENVRESSE ISABELLE
申请号：
SV2017005530
公开号：
SV2017005530A
申请日:
2017.09.08
申请国别(地区):
SV
年份:
2018
代理人:
摘要：
Combination: component A: one or more compounds, composed of 2.3-dihydromidazo [1.2-c] quinazolina de communal (A1) or (A2),Or a physiologically acceptable salt, solution, hydrate or stereoisomer； component B: one or more 5 - (1-benzotiofen-2-il) pirrolo [2.1-f] [1.2.4] - 4-trioxy-amine, replaced by common fluorine (b)；Or a physiologically acceptable salt, solution, hydrate or stereoisomer, some or all of which may be selected as drug formulations, available for use, and can be managed simultaneously, in parallel, separately or continuously. Oral, intravenous, thoracic, local, intraperitoneal, or intranasal catheters are interdependent； drugs for the treatment or prevention of czer are formulated using these combinations； including such combinations of drug kits； The use of biological ark is the loss of PTEN or Fbxw7 tumor inhibitor,It is used to predict the sensitivity and / or resistance of patients to the compound, and provide an informed dose to improve the sensitivity and / or treatment resistance； it is used to determine whether PTEN or Fbxw7 tumor inhibitor has been lost；AND A METHOD FOR DETERMINING DISTURBANCES IN PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 AND / OR FGFR4. LOSS OF PTEN AND ALTERATION OF PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 Y / O FGFR4.COMBINACIONES DE: COMPONENTE A : UNO O MÁS COMPUESTOS DE 2,3-DIHIDROIMIDAZO[1,2-C]QUINAZOLINA DE FÓRMULA GENERAL (A1) O (A2), O UNA SAL, SOLVATO, HIDRATO O ESTEREOISÓMERO FISIOLÓGICAMENTE ACEPTABLE DE LOS MISMOS； COMPONENTE B : UNO O MÁS COMPUESTOS DE 5-(1-BENZOTIOFEN-2-IL)PIRROLO[2,1-F][1,2,4]-TRIAZIN-4- AMINA SUSTITUIDA DE FÓRMULA GENERAL (B), O UNA SAL, SOLVATO, HIDRATO O ESTEREOISÓMERO FISIOLÓGICAMENTE ACEPTABLE DE LOS MISMOS； EN LAS CUALES OPCIONALMENTE ALGUNOS O TODOS LOS COMPONENTES ESTÁN EN FORMA DE UNA FORMULACIÓN FARMACÉUTICA LA CUAL ESTÁ LISTA PARA SU UTILIZACIÓN Y SE ADMINISTRA SIMULTÁNEA, CONCURRE
